StockData
Pfizer Inc logo

Pfizer Inc (PFE) stock

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.47−0.39 (-1.35%)

Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%

Pfizer gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Pfizer's gross profit for the twelve months ending Jun 28, 2026 was $46.61B, up 1.2% year over year. For fiscal 2025 it was $46.51B, up 1.6% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $66.83B in fiscal 2022.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$46.51B+1.6%
FY2024Dec 31, 2024$45.78B+32.3%
FY2023Dec 31, 2023$34.60B-48.2%
FY2022Dec 31, 2022$66.83B+32.4%
FY2021Dec 31, 2021$50.47B+52.2%
FY2020Dec 31, 2020$33.17B+1.0%
FY2019Dec 31, 2019$32.85B+3.2%
FY2018Dec 31, 2018$31.84B-22.9%
FY2017Dec 31, 2017$41.32B+2.0%
FY2016Dec 31, 2016$40.50B+3.3%
FY2015Dec 31, 2015$39.20B-2.1%
FY2014Dec 31, 2014$40.03B-4.7%
FY2013Dec 31, 2013$42.00B-6.3%
FY2012Dec 31, 2012$44.84B-7.6%
FY2011Dec 31, 2011$48.54B-3.7%
FY2010Dec 31, 2010$50.38B+23.4%
FY2009Dec 31, 2009$40.81B+1.6%
FY2008Dec 31, 2008$40.18B+8.1%
FY2007Dec 31, 2007$37.18B–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 28, 2026$10.94B+0.6%
Q1 FY2026Mar 29, 2026$10.90B+0.3%
Q4 FY2025Dec 31, 2025$12.29B+3.6%
Q3 FY2025Sep 28, 2025$12.48B+0.3%
Q2 FY2025Jun 29, 2025$10.88B+8.9%
Q1 FY2025Mar 30, 2025$10.87B-5.5%
Q4 FY2024Dec 31, 2024$11.85B+69.2%
Q3 FY2024Sep 29, 2024$12.44B+194.6%
Q2 FY2024Jun 30, 2024$9.98B+2.2%
Q1 FY2024Mar 31, 2024$11.50B-15.4%
Q4 FY2023Dec 31, 2023$7.01B-54.8%
Q3 FY2023Oct 1, 2023$4.22B-74.5%
Q2 FY2023Jul 2, 2023$9.77B-48.8%
Q1 FY2023Apr 2, 2023$13.60B-13.2%
Q4 FY2022Dec 31, 2022$15.49B+9.8%
Q3 FY2022Oct 2, 2022$16.58B+17.5%
Q2 FY2022Jul 3, 2022$19.09B+60.4%
Q1 FY2022Apr 3, 2022$15.68B+51.3%
Q4 FY2021Dec 31, 2021$14.10B+61.8%
Q3 FY2021Oct 3, 2021$14.10B+70.5%
Q2 FY2021Jul 4, 2021$11.90B+48.1%
Q1 FY2021Apr 4, 2021$10.36B+27.2%
Q4 FY2020Dec 31, 2020$8.72B+522.6%
Q3 FY2020Sep 27, 2020$8.27B-17.9%
Q2 FY2020Jun 28, 2020$8.04B-24.8%
Q1 FY2020Mar 29, 2020$8.14B-23.8%
Q4 FY2019Dec 31, 2019$1.40B+310.6%
Q3 FY2019Sep 29, 2019$10.08B-5.0%
Q2 FY2019Jun 30, 2019$10.69B+1.3%
Q1 FY2019Mar 31, 2019$10.69B+3.3%
Q4 FY2018Dec 31, 2018$341.00M-96.7%
Q3 FY2018Sep 30, 2018$10.60B+2.7%
Q2 FY2018Jul 1, 2018$10.55B+3.1%
Q1 FY2018Apr 1, 2018$10.34B+0.3%
Q4 FY2017Dec 31, 2017$10.45B+0.3%
Q3 FY2017Oct 1, 2017$10.32B+3.7%
Q2 FY2017Jul 2, 2017$10.24B–
Q1 FY2017Apr 2, 2017$10.31B–
Q4 FY2016Dec 31, 2016$10.42B–
Q3 FY2016Oct 2, 2016$9.96B–

More Pfizer figures

See a number that looks wrong?